Tselis et al Arnon R. 1996. The development of Cop 1 (Copaxone), an innovative drug for the treatment of multiple sclerosis: personal reﬂections. Immunol Lett, 50:1–15. Bakalash S, Schlomo G, Aloni E, et al. 2005. T cell-based vaccination for morphological and functional neuroprotection in a rat model of chroni- cally elevated intraocular pressure. J Mol Med, 83:904–16. Balabanov R, Lisak D, Beaumont T, et al. 2001. Expression of urokinase plasminogen activator receptor on monocytes from patients with relapsing-remitting multiple sclerosis: effect of glatiramer acetate (copolymer 1). Clin Diagn Lab Immunol, 8:1196–203. Benner E, Mosley R, Destache C, et al. 2004. Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson’s disease. Proc Nat Acad Sci U S A, 101:9435–40. Boneschi F, Rovaris M, Johnson K, et al. 2003. Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta- analysis of three double-blind, randomized, placebo-controlled clinical trials. Mult Scler, 9:349–55. Bornstein M, Miller A, Slagle S, et al. 1987. A pilot trial of Cop 1 in exac- erbating-remitting multiple sclerosis. New Engl J Med, 317:408–14. Bornstein M, Miller A, Slagle S, et al. 1991. A placebo-controlled, double- blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis. Neurology, 41:533–9. Bornstein M, Miller A, Teitelbaum D, et al. 1981. Multiple sclerosis: trial of a synthetic polypeptide. Ann Neurol, 11:317–19. Brenner T, Arnon R, Sela M, et al. 2001. Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone. J Neuroimmunol, 115:152–60. Burns J, Littleﬁeld K. 1991. Failure of copolymer 1 to inhibit the human T cell response to myelin basic protein. Neurology, 41:1317–19. Caramanos Z, Arnold D. 2005. Evidence for use of glatiramer acetate in multiple sclerosis. Lancet Neurol, 4:74–5. Chen M, Gran B, Costello K, et al. 2001. Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS. Mult Scler, 7:209–19. Chen M, Valenzuela R, Dhib-Jalbut S. 2003. Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factor. J Neurol Sci, 215:37–44. Comi G, Filippi M, Wolinsky J, et al. 2001. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol, 49:290–7. Comi G, Hartung H-P, Boneschi F. 2005. Evidence for use of glatiramer acetate in multiple sclerosis. Lancet Neurol, 4:75–6. Duda P, Schmied M, Cook S, et al. 2000. Glatiramer acetate induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest, 105:967–76. Farina C, Bergh F, Abrecht H, et al. 2001. Treatment of multiple sclerosis with Copaxone (COP). Elispot assay detects COP-induced interleukin-4 and interferon-gamma response in blood cells. Brain, 124:705–19. Farina C, Vargas V, Heydari N, et al. 2002. Treatment with glatiramer acetate induces speciﬁc IgG4 antibodies in multiple sclerosis patients. J Neuroimmunol, 123:188–92. Farina C, Weber M, Meinl E, et al. 2005. Glatiramer acetate in multiple sclerosis: an update on potential mechanisms of action. Lancet Neurol, 4:567–75. Filippi M, Rovaris M, Rocca M, et al. 2001. Glatiramer acetate reduces the proportion of new MS lesions evolving into “black holes.” Neurology, 57:731–3. Fridkis-Hareli M, Teitelbaum D, Gurevich E, et al. 1994. Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-present- ing cells—speciﬁcity and promiscuity. Proc Nat Acad Sci U S A, 91:4872–6. Ge Y, Grossman R, Udupa J, et al. 2000. Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS. Quantitative MR assessment. Neurology, 54:813–17. Hussien Y, Sanna A, Soderstrom M, et al. 2001. Glatiramer acetate and IFN-beta act on dendritic cells in multiple sclerosis. J Neuroimmunol, 121:102–10. Johnson K, Brooks B, Cohen J, et al. 1998. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology, 50:701–8. Johnson K, Brooks B, Cohen J, et al. 1995. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology, 45:1268–76. Johnson K, Ford C, Lisak R, et al. 2005. Neurologic consequence of delay- ing glatiramer acetate therapy for multiple sclerosis: 8 year data. Acta Neurol Scand, 111:42–7. Kalinski P, Hilkens C, Wierenga E, et al. 1999. T cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol Today, 20:561–7. Karandikar N, Crawford M, Yan X, et al. 2002. Glatiramer acetate (copax- one) therapy induces CD8 T cell responses in patients with multiple sclerosis. J Clin Invest, 109:641–9. Kerschensteiner M, Gallmeier E, Behrens L, et al. 1999. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inﬂammatory brain lesions: a neuroprotective role of inﬂammation. J Exp Med, 189:865–70. Khan O, Shen Y, Caon C, et al. 2005. Axonal metabolic recovery and poten- tial neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis. Mult Scler, 11:646–51. Kidd D, Barkhof R, McConnell R, et al. 1999. Cortical lesions in multiple sclerosis. Brain, 122:17–26. Kim H, Ifergan I, Antel J, et al. 2004. Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. J Immunol, 172:7144–53. Kipnis J, Yoles E, Porat Z, et al. 2000. T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies. Proc Nat Acad Sci U S A, 97:7446–51. Kurtzke J. 1983. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology, 33:1444–52. Kutzelnigg A, Lucchinetti C, Stadelmann C, et al. 2005. Cortical demy- elination and diffuse white matter injury in multiple sclerosis. Brain, 128:2705–12. Lisak R, Zweiman B, Blanchard N, et al. 1983. Effect of treatment with copolymer 1 (Cop-1) on the in vivo and in vitro manifestations of experi- mental allergic encephalomyelitis (EAE). J Neurol Sci, 62:281–93. Lucchinetti C, Bruck W, Parisi J, et al. 2000. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol, 47:707–17. Munari L, Lovati R, Boiko A. 2003. Therapy with glatiramer acetate for multiple sclerosis (review). The Cochrane Database of Systematic Reviews: CD004678. Neuhaus O, Farina C, Yassouridis A, et al. 2000. Multiple sclerosis: com- parison of copolymer-1-reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proc Nat Acad Sci U S A, 97:7452–7. Peterson J, Bo L, Mork S, et al. 2001. Transected neurites, apoptotic neu- rons, and reduced inﬂammation in cortical multiple sclerosis lesions. Ann Neurol, 50:389–400. Qin Y, Zhang D, Prat A, et al. 2000. Characterization of T cell lines derived from glatiramer-acetate-treated multiple sclerosis patients. J Neuroim- munol, 108:201–6. Ragheb S, Abramczyk S, Lisak D, et al. 2001. Long-term therapy with glatiramer acetate in multiple sclerosis: effect on T cells. Mult Scler, 7:43–7. Raine C, Cannella B, Hauser S, et al. 1999. Demyelination in pri- mate autoimmune encephalomyelitis and acute multiple sclerosis lesions: a case for antigen-specific antibody mediation. Ann Neurol, 46:144–60. 266 Neuropsychiatric Disease and Treatment 2007:3(2)